Akari Therapeutics PLC (NASDAQ:AKTX) Given Average Recommendation of “Moderate Buy” by Brokerages

Akari Therapeutics PLC (NASDAQ:AKTX) has received an average rating of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $32.3333.

AKTX has been the subject of several recent research reports. Weiss Ratings raised shares of Akari Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. Maxim Group raised Akari Therapeutics from a “hold” rating to a “buy” rating and set a $30.00 target price for the company in a research note on Monday, July 20th. Alliance Global Partners raised Akari Therapeutics to a “strong-buy” rating in a research report on Friday. Finally, Wall Street Zen upgraded shares of Akari Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 22nd.

Akari Therapeutics Trading Up 2.4%

AKTX stock opened at $9.38 on Tuesday. The business’s fifty day moving average price is $9.26 and its 200 day moving average price is $9.03. Akari Therapeutics has a 12-month low of $3.02 and a 12-month high of $49.60.

About Akari Therapeutics

Akari Therapeutics plc is a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory diseases. The company’s research is focused on modulating the complement system and inflammatory pathways that contribute to tissue damage and disease progression.

Akari’s lead investigational product is nomacopan, a recombinant small protein originally derived from tick saliva. Nomacopan is designed to inhibit complement component C5 and leukotriene B4, two pathways involved in inflammation.